Compare Coinbase Global, Inc. (COIN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Novavax Inc — how do they compare? Coinbase Global, Inc. trades at $181.03 (market cap $45.38B), while Novavax Inc trades at $13.02 (market cap $1.82B). The key difference: Coinbase Global, Inc. is far larger — about 24.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Novavax Inc for 59 Days on average.
| COIN | NVAX | |
|---|---|---|
Market Cap | $45.38B | $1.82B |
Volume | 11,013,940 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $387.00 | $12.56 |
52-Week Low | $141.09 | $6.22 |
Typical Hold Time | 78 Days | 59 Days |
Enterprise Value | $43.03B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coinbase Global (COIN) trades at $181.09, up 1.48% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported $7.18B revenue in 2025 with $1.26B net income, though recent quarterly earnings have missed expectations. Positive developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup, while analyst consensus remains bullish with a $211.91 price target.
The stock presents growth potential from expanding derivatives business and institutional partnerships, but faces risks from earnings volatility and crypto market exposure. With 55% analyst buy ratings and strong cash flow generation, COIN offers upside to price targets, though investors should monitor execution on profitability goals amid competitive pressures.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
